Kymera Therapeutics (KYMR) | Stock Overview & Key Data
Kymera Therapeutics Performance Comparison
Stock Range
Today's Range
Low: $42.26
High: $44.48
on August 22, 2025
52 Week Range
Low: $19.44
High: $53.27
on April 9, 2025
on September 26, 2024
All-Time High: $91.92 on December 28, 2020
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$3.0B
EPS
-3.49
P/E Ratio (TTM)
-13.94
Forward P/E
-13.69
P/B Ratio
3.09
PEG Ratio
-0.22
Div. Yield
N/A
ROE
-33.26%
Beta
2.184
Debt to Equity
8.82
Financial Highlights
Profitability
Gross Margin
N/A
Operating Margin
-736.82%
Profit Margin
0.00%
Returns and Earnings
Return on Assets (TTM)
-19.92%
Return on Equity (TTM)
-33.26%
EBITDA
$-305.1M
Net Income (TTM)
$-275.4M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$0.69
Quarterly Revenue Growth (YoY)
-55.30%
Quarterly Earnings Growth (YoY)
-55.26%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Kymera Therapeutics KYMR | 3.04B Mid-cap | 2.50% | -5.65% | 41.35% | 15.70% | 4.16% | -10.86% | 37.17% | 27.97% |
| Vertex VRTX | 100.19B Large-cap | 1.83% | -13.31% | -8.70% | -17.92% | -2.05% | -17.41% | 41.10% | 47.23% |
| Regeneron REGN | 62.88B Large-cap | 5.69% | 9.65% | -1.07% | -14.59% | -16.36% | -50.12% | 0.33% | -0.74% |
| BridgeBio Pharma BBIO | 9.39B Mid-cap | -1.86% | 9.43% | 52.95% | 36.31% | 78.12% | 98.46% | 379.29% | 69.75% |
| Madrigal MDGL | 8.46B Mid-cap | 9.62% | 23.01% | 46.84% | 21.07% | 29.74% | 61.07% | 481.06% | 281.74% |
| Blueprint Medicines BPMC | 8.37B Mid-cap | 0.12% | 1.05% | 53.79% | 15.63% | 48.46% | 12.60% | 149.54% | 73.38% |
Ownership & Short Interest
Insider Ownership
2.45%
Institutional Ownership
110.19%
Shares Short
8M
Short Ratio
12.29
Short % of Shares Outstanding
13.70%
Average 10-Day Volume
829K
Average 90-Day Volume
644K
Kymera Therapeutics Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Kymera Therapeutics would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is KYMR's 52-week high and low?
- In the last 52 weeks, Kymera Therapeutics reached a high of $53.27 (on September 26, 2024) and a low of $19.44 (on April 9, 2025).
- What is the market cap and P/E ratio for KYMR?
- Curious about Kymera Therapeutics's size and valuation? Its market capitalization stands at 3.04B. When it comes to valuation, the P/E ratio (trailing twelve months) is -13.94, and the forward P/E (looking ahead) is -13.69.
- Does KYMR pay dividends? If so, what's the yield?
- As for dividends, Kymera Therapeutics isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Kymera Therapeutics's main competitors or similar companies to consider before investing?
When looking at Kymera Therapeutics, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Vertex
VRTX100.19B Healthcare Biotechnology -17.41% 41.10% Regeneron
REGN62.88B Healthcare Biotechnology -50.12% 0.33% BridgeBio Pharma
BBIO9.39B Healthcare Biotechnology 98.46% 379.29% Madrigal
MDGL8.46B Healthcare Biotechnology 61.07% 481.06% Blueprint Medicines
BPMC8.37B Healthcare Biotechnology 12.60% 149.54% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Kymera Therapeutics Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Kymera Therapeutics's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -33.26%, the Debt to Equity ratio from the most recent quarter is 8.82, and its Gross Profit Margin stands at N/A.
- What is the recent revenue and earnings growth for KYMR?
- Looking at Kymera Therapeutics's growth, its revenue over the trailing twelve months (TTM) was $45M. Compared to the same quarter last year (YoY), quarterly revenue grew by -55.30%, and quarterly earnings saw a YoY growth of -55.26%.
- How much of KYMR stock is held by insiders and institutions?
- Wondering who owns Kymera Therapeutics stock? Company insiders (like executives and directors) hold about 2.45% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 110.19%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.